HMOX1 and Hepatic fibrosis: The PBP‐NPs containing HO‐1 inducers have diverse therapeutic advantages that could be achieved simultaneously: 1) avoiding off target effects of HO‐1, 2) inducing brown adipogenesis to exhaust circulating lipids, 3) lowering systemic inflammation caused by obese ATMs, 4) decreasing hepatic accumulation of lipids and cytokines, 5) normalizing hepatic lipid metabolism and protecting from hepatic apoptosis, 6) inhibiting activation of hepatic macrophages to initiate hepatic fibrosis.